Laurus Labs has said it has received the license from Defence Research and Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug 2-Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing.
“Laurus Labs has already applied with the Central Drugs Standard Control Organisation (CDSCO) for emergency use authorization (EUA) for 2DG,” it added.
- UK Self-Driving Startup Wayve Raised USD 1.05 Billion From SoftBank Group
- Apple Working on a Project To Develop Chip Running AI Softwares in Data Centres
- GST on Corporate Guarantees Temporily Ceased for Holding Companies in India
- Avantel Limited Shares Gain 2% on Securing Rs 2.29 Crore Order
- India Allowed the Export of Non-Basmati White Rice to Mauritius Through National Cooperative Exports
On June 28, pharma major Dr Reddy’s announced the commercial launch of 2DG at a maximum retail price of Rs 990 per sachet. Shares of Laurus Labs were trading at Rs 674.20 per scrip on BSE, up 1.08 per cent from the previous close.